News

Trend Structure: Breakout Marks Shift in Market Sentiment

Strategic Partnership in Ophthalmology Devices and Group Purchasing Organizations (GPOs)Iridex Corporation, a provider of laser-based medical systems for ophthalmology, has entered into a partnership with EyeProGPO, a U.S.-focused group purchasing organization serving more than 1,800 ophthalmology practices, ambulatory surgery centers, and hospitals. The agreement …

AtaiBeckley Inc. has reported Phase 2a clinical data for BPL-003, an intranasal psychedelic-based therapy targeting treatment-resistant depression (TRD), highlighting both rapid onset and sustained efficacy. The findings arrive as investor and industry attention toward next-generation mental health treatments continues to expand, particularly in segments …

FDA Orphan Drug Designation Expands Scope in Pediatric Brain Cancer TreatmentPlus Therapeutics has secured U.S. FDA Orphan Drug Designation for REYOBIQ, its investigational radiotherapeutic targeting pediatric malignant gliomas. Notably, the designation extends beyond the company’s initial request to include pediatric ependymoma, broadening the potential …

iBio, Inc. has taken a notable step in its development trajectory with regulatory clearance in Australia to initiate a first-in-human Phase 1 trial for IBIO-600. The Clinical Trial Notification acknowledgement from the Therapeutic Goods Administration, alongside ethics approval, enables the company to begin dosing …

UroGen Pharma Expands Clinical Engagement in LG-UTUC Treatment LandscapeUroGen Pharma Ltd. has introduced its “LG-UTUC Luminaries” initiative, a clinician- and institution-focused program aimed at advancing care standards for low-grade upper tract urothelial cancer (LG-UTUC). The initiative underscores the company’s broader strategy of embedding itself …

Single-Patient Case Study Highlights Early Signal for Phyto-N in Cancer CachexiaCuranex Pharmaceuticals drew market attention after presenting a single-patient case study suggesting potential symptomatic benefits of its lead candidate, Phyto-N, in cancer cachexia and advanced cancer supportive care. The patient, treated for a pancreatic …